The impact of different presenilin 1 andpresenilin 2 mutations on amyloid deposition, neurofibrillary changes and neuronal loss in the familial Alzheimer's disease brain

To assess the influence of the presenilin 1 (PS1) and 2 (PS2) mutations on amyloid deposition, neurofibrillary tangle (NFT) formation and neuronal loss, we performed stereologically based counts in a high-order association cortex, the superior temporal sulcus, of 30 familial Alzheimer's disease...

Full description

Saved in:
Bibliographic Details
Published inBrain (London, England : 1878) Vol. 122; no. 9; pp. 1709 - 1719
Main Authors Gómez-Isla, Teresa, Growdon, Whitfield B., McNamara, Megan J., Nochlin, David, Bird, Thomas D., Arango, Juan Carlos, Lopera, Francisco, Kosik, Kenneth S., Lantos, Peter L., Cairns, Nigel J., Hyman, Bradley T.
Format Journal Article
LanguageEnglish
Published Oxford University Press 01.09.1999
Subjects
Online AccessGet full text
ISSN0006-8950
1460-2156
DOI10.1093/brain/122.9.1709

Cover

Loading…
More Information
Summary:To assess the influence of the presenilin 1 (PS1) and 2 (PS2) mutations on amyloid deposition, neurofibrillary tangle (NFT) formation and neuronal loss, we performed stereologically based counts in a high-order association cortex, the superior temporal sulcus, of 30 familial Alzheimer's disease cases carrying 10 different PS1 and PS2 mutations, 51 sporadic Alzheimer's disease cases and 33 non-demented control subjects. All the PS1 and PS2 mutations assessed in this series led to enhanced deposition of total Aβ and Aβx-42/43 but not Aβx-40 senile plaques in the superior temporal sulcus when compared with brains from sporadic Alzheimer's disease patients. Some of the PS1 mutations studied (M139V, I143F, G209V, R269H, E280A), but not others, were also associated with faster rates of NFT formation and accelerated neuronal loss in the majority of the patients who harboured them when compared with sporadic Alzheimer's disease patients. In addition, our analysis showed that dramatic quantitative differences in clinical and neuropathological features can exist even among family members with the identical PS mutation. This suggests that further individual or pedigree genetic or epigenetic factors are likely to modulate PS phenotypes strongly.
Bibliography:Dr Teresa Gómez-Isla, Department of Neurology, 420 Delaware St SE, University of Minnesota, Box 295 FUMC, Minneapolis, MN 55455, USA E-mail: gomez010@tc.umn.edu
local:1221709
PII:1460-2156
ark:/67375/HXZ-KPWSBG0N-4
istex:2EE32825A7143B1E090D0B4354C1268B03D454F1
ISSN:0006-8950
1460-2156
DOI:10.1093/brain/122.9.1709